Thomas (Tommy) Tobin Counsel

Perkins Coie is pleased to announce that 46 lawyers have been promoted to the firm’s counsel position, effective January 1, 2024.

Brian Sylvester and Tommy Tobin were quoted in "Cultivated Meat Labeling Puzzle Could Bring Legal Headaches," an article in Food Dive about how debates over package labeling rules related to cultivated meat could still create issues for companies in the space.

Brian Sylvester and Tommy Tobin were quoted in "The Slow Road to Retail: How Consumers are Dictating Cultivated Meat’s Strategy," an article in Food Dive about how consumer acceptance surrounding cultivated meat is a major reason why the product is only available at exclusive restaurants. 

Tommy Tobin was quoted in the CNN article "McDonald’s and Wendy’s Win False Advertising Lawsuit" about the record number of food litigation lawsuits in recent years.

Tommy Tobin was quoted in the CNN article "Burgers and Tacos Don’t Look Like They Do in Ads. Lawsuits are Trying to Change That" about the growing number of food litigation lawsuits in recent years.

Brian Sylvester and Tommy Tobin were quoted in "The Sticky Regulatory Landscape of Cultivated Meat and What to Expect Next," an article in Food Dive about where the regulation surrounding cultivated meat is heading and what that means for companies and the major players in the industry.

Perkins Coie is proud to announce that 388 of its lawyers have been recognized by Best Lawyers® 2024. A total of 275 attorneys were selected by their peers for inclusion in the 2024 edition of The Best Lawyers in America® and 113 attorneys were selected for inclusion in the 2024 edition of Best Lawyers: Ones to Watch.

James Williams, Thomas Tobin, Andrew Kline, Holly Martinez and Caleb Bacos were mentioned in “DEA Wrongly Refuses To Reconsider Psilocybin, 9th Circ. Told,” an article Law360, regarding the case of a Washington state clinic fighting for terminally ill patients' right to use psilocybin.

Tommy Tobin and Kristine Kruger were quoted in “California Health Committee Approves Ban on Five Food Additives in Landmark Bill Co-Sponsored by EWG and Consumer Reports,” an article in Food Navigator, addressing food additives.

Thomas Tobin was quoted in "How Federal Weed Legalization Would Impact Washington State" an article in Crosscut, regarding the import/export of marijuana in Washington.

Perkins Coie lawyers were mentioned in “DEA Erred In Rejecting Psilocybin Therapy, 9th Circ. Hears,” an article Law360, regarding a doctor who is urging the U.S. Court of Appeals for the Ninth Circuit to find that the U.S. Drug Enforcement Administration (DEA) erred when it stated that psilocybin, the psychedelic compound produced by certain mushrooms, has no medical value.

Senior Counsel Kristine Kruger and Associate Tommy Tobin were quoted in "Lawyers on What the Cosmetics Industry Needs To Know About MoCRA," an article in CosmeticsDesign, regarding the new authority and oversight the U.S. Food and Drug Administration (FDA) will have in different areas of cosmetic product regulation due to the Modernization of Cosmetics Regulation Act of 2022 (MoCRA).

Seattle Associate Tommy Tobin was named one of the Top 40 Young Lawyers by the American Bar Association (ABA) for 2022.

Perkins Coie is pleased to announce that its Cannabis Law Industry Group advised PepsiCo regarding legal compliance for its hemp seed ingredient for the global food, snack, and beverage company’s new energy drink Rockstar Unplugged.

James Davis was quoted in “United Policyholders Backs 9th Circ. Virus Coverage Appeals,” an article in Law360, regarding the amicus briefs filed in the U.S. Court of Appeals for the Ninth Circuit by United Policyholders and two other organizations in support of Washington state businesses seeking to revive their COVID-19 coverage suits against an Allianz unit. Bradley Dlatt and Tommy Tobin were also mentioned as counsel for United Policyholders.

Associate Tommy Tobin was interviewed in “CBD Law: Unsubstantiated Health Claims, Non-Uniform Regulations State to State Pose Roadblocks,” an article in CosmeticsDesign, about where CBD stands legally in the United States.

David Biderman, Charles Sipos, and Tommy Tobin were mentioned in “Amazon Escapes Suit Over Purchased Video Prices, For Now,” an article in Law360, regarding their representation of Amazon in Amanda Caudel v. Amazon.com Inc.

Perkins Coie is pleased to announce that five attorneys and the firm were recognized by JD Supra in the 2021 Readers’ Choice Awards, which acknowledge the top authors and law firms for their thought leadership on key topics.

Associate Tommy Tobin was quoted in “A Lawyer Filed More Than 100 Lawsuits Over Vanilla Flavoring in Foods and Drinks, Arguing Most of it Is Fake,” an article in Business Insider,* regarding food litigation in 2020 being dominated by vanilla cases.

Perkins Coie is pleased to announce that Barak Cohen, the firmwide chair of Perkins Coie’s Cannabis Law industry group, and Associate Michael Bleicher have edited the first American Bar Association treatise on cannabis law.

Perkins Coie has launched a new blog covering the cannabis industry, including marijuana, CBD, and hemp-related businesses, that will provide timely updates and insights on the latest regulations, as well as evolving litigation, technology, and transaction trends impacting the sector.

Perkins Coie has released its 2019 Food Litigation Year in Review report, which shows a jump in class action litigation to a record-breaking 173 new lawsuits. The 2019 report also shows an upward trend in class action complaints focused on the dietary supplement and pet food sectors.

Perkins Coie's Food Litigation Year in Review 2019 was mentioned in the Food Navigator article, "Are You at Risk of a Class Action Lawsuit? Perkins Coie Outlines Key Areas of Vulnerability for Food & Beverage Brands," regarding the firm's summary of the past year’s key litigation outcomes, regulatory developments, and filing data in the food and beverage industry.

Perkins Coie was quoted in the Food Processing article, "FDA Letters, Lawsuits Meet the First Generation of CBD Products," regarding the FDA warning letters that were issued to companies selling products containing CBD at the end of November, which explicitly stated that the FDA has not proclaimed CBD as safe yet.